The Precision Peptide Company Orders 20,000 Thymosin Alpha-1 Patches for Commercial Launch
Initial U.S. production run moves the Company's second transdermal peptide product from successful testing toward direct-to-consumer and wholesale availability
Highlights
- Order placed for 20,000 units of the Company's needle-free Thymosin Alpha-1 transdermal patch in preparation for commercial release
- TA1 is a naturally occurring peptide studied for its immune-modulating properties, historically delivered by injection¹
- The Company believes it could be among the first to market with a Thymosin Alpha-1 transdermal patch.
- Second product to move from the Company's transdermal development pipeline into commercial production
- Each patch is formulated to deliver 2 mg of TA1, consistent with the results reported in the Company's September 8, 2026 news release
- 100% manufactured and tested in the United States
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has placed an order for 20,000 units of its Thymosin Alpha-1 ("TA1") transdermal patch (the "Patch"). The order is intended to support the Patch's planned commercial release and represents the Company's initial commercial production run of the product. Each Patch is formulated to deliver 2 mg of TA1.
The order follows the Company's September 8, 2026 news release, "The Precision Peptide Company Advances Thymosin Alpha-1 Patch into Formal U.S. Testing," regarding the development of its Thymosin Alpha-1 transdermal patch. The order is for patches formulated with a 2 mg dose of Thymosin Alpha-1.
TA1 is a naturally occurring peptide present in the thymus that has been studied for its immune-modulating properties.¹ In the clinical studies included in a 2025 systematic review and meta-analysis, TA1 was administered by subcutaneous injection.¹ That study did not evaluate the Company's patch, which remains under development and testing. The Patch is designed as a wearable wellness product that applies directly to the skin, with no injections, no reconstitution and no user-administered dose measurement.
The Patch is the second product to advance through the Company's transdermal development pathway into commercial production, following the BPC-157 patch. Based on its review of currently available products, the Company believes it could be among the first to market with a TA1 transdermal patch.

